Evaluation of the Efficacy of Transcatheter Intervention, Surgery, and Pharmacological Treatment of Functional Mitral Regurgitation — A Bayesian Network Meta-Analysis with ≥12-Month Follow-up
DOI:
https://doi.org/10.59958/hsf.7387Keywords:
functional mitral regurgitation, network meta-analysis, transcatheter intervention, optimal pharmacological therapy, surgical treatmentAbstract
Aim: Evaluate, using a Bayesian network meta-analysis system, the long-term prognosis of patients with functional mitral regurgitation (FMR) undergoing individual or combined treatment with percutaneous intervention, surgical intervention, or optimal medical therapy. Compare the prognostic outcomes of the different treatment modalities. Methods: Computerized searches of Embase, PubMed, and the Cochrane Library databases were performed. Randomized controlled trials (RCTs) and observational studies were searched to compare prognoses following transcatheter interventions, surgery, and optimal pharmacological treatment for FMR, all with a construction timeframe of 21 October 2023. The primary endpoint event was all-cause mortality. The secondary endpoint events were heart failure readmission rate, mitral regurgitation (MR) ≤2+ improvement rate, New York Heart Association (NYHA) improvement rate (improvement to I–II), and degree of left ventricular ejection fraction (LVEF) improvement. Results: Twenty-six (26) papers were included, comprising 10 RCTs and 16 observational studies involving 5443 patients. A network meta-analysis showed no significant difference in prognosis for all-cause mortality among transcatheter interventions, surgical procedures, and optimal pharmacological treatments. For heart failure readmission rates, mitral valve surgery was superior to MitraClip (odds ratio (OR) = 11.82; 95% confidence interval (CI): 1.67, 90.13). For NYHA (improvement to I–II) improvement rates, the results showed no significant differences for the various mitral interventions. For MR ≤2+ improvement rates, the MitraClip (OR = 3.07; 95% CI: 2.42, 3.76), MitraClip+Guideline-directed medical therapy (GDMT) (OR = 2.93; 95% CI: 2.38, 3.52), mitral valve surgery (OR = 3.01; 95% CI: 2.24, 3.8), and annuloplasty (OR = 4.31; 95% CI: 3.12, 5.58) were superior to GDMT, and mitral valve surgery (OR = 0.07; 95% CI: –0.45, 0.62) was superior to MitraClip+GDMT. For the degree of improvement in LVEF, Carillon+GDMT (mean difference (MD) = –0.97; 95% CI: –1.72, –0.22) was superior to GDMT, mitral valve surgery was superior to Carillon+GDMT (MD = 4.67; 95% CI: 0.92, 8.39); MitraClip+GDMT (MD = 4.01; 95% CI: 1.28, 6.66), GDMT (MD = 3.71; 95% CI: 0.04, 7.35), and annuloplasty were superior to mitral valve surgery (MD = –6.42; 95% CI: –11.96, –0.78). Conclusion: There were no significant differences among the three treatment modalities of transcatheter intervention, surgery, and optimal drug therapy in improving all-cause mortality hard endpoint events, and no significant differences were seen in the rates of heart failure readmission and NYHA improvement (improvement to I–II). However, surgery was superior to transcatheter intervention and optimal drug therapy in terms of improvement in the degree of regurgitation and LVEF.
References
Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet (London, England). 2006; 368: 1005–1011.
Dziadzko V, Dziadzko M, Medina-Inojosa JR, Benfari G, Michelena HI, Crestanello JA, et al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome. European Heart Journal. 2019; 40: 2194–2202.
Dziadzko V, Clavel MA, Dziadzko M, Medina-Inojosa JR, Michelena H, Maalouf J, et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet (London, England). 2018; 391: 960–969.
Dal-Bianco JP, Aikawa E, Bischoff J, Guerrero JL, Handschumacher MD, Sullivan S, et al. Active adaptation of the tethered mitral valve: insights into a compensatory mechanism for functional mitral regurgitation. Circulation. 2009; 120: 334–342.
Tibayan FA, Rodriguez F, Langer F, Zasio MK, Bailey L, Liang D, et al. Annular remodeling in chronic ischemic mitral regurgitation: ring selection implications. The Annals of Thoracic Surgery. 2003; 76: 1549–1549–54; discussion 1554–5.
Agricola E, Ielasi A, Oppizzi M, Faggiano P, Ferri L, Calabrese A, et al. Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. European Journal of Heart Failure. 2009; 11: 581–587.
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2022; 43: 561–632.
Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology. 2011; 64: 163–171.
Lin YY, Gao HF, Yang X, Zhu T, Zheng XX, Ji F, et al. Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis. Breast (Edinburgh, Scotland). 2022; 66: 126–135.
Okuno T, Praz F, Kassar M, Biaggi P, Mihalj M, Külling M, et al. Surgical versus transcatheter repair for secondary mitral regurgitation: A propensity score-matched cohorts comparison. The Journal of Thoracic and Cardiovascular Surgery. 2023; 165: 2037–2046.e4.
Ludwig S, Conradi L, Cohen DJ, Coisne A, Scotti A, Abraham WT, et al. Transcatheter Mitral Valve Replacement Versus Medical Therapy for Secondary Mitral Regurgitation: A Propensity Score-Matched Comparison. Circulation. Cardiovascular Interventions. 2023; 16: e013045.
Leibowitz D, Haberman D, Goland S, George J, Beeri R, Planer D, et al. Outcomes following transcatheter repair in patients with functional mitral regurgitation not receiving guideline directed medical therapy in Israel. BMC Cardiovascular Disorders. 2023; 23: 304.
Tanaka T, Kavsur R, Spieker M, Iliadis C, Metze C, Brachtendorf BM, et al. Guideline-directed medical therapy after transcatheter edge-to-edge mitral valve repair. Heart (British Cardiac Society). 2022; 108: 1722–1728.
Lim DS, Smith RL, Gillam LD, Zahr F, Chadderdon S, Makkar R, et al. Randomized Comparison of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients. JACC. Cardiovascular Interventions. 2022; 15: 2523–2536.
Anker SD, Starling RC, Khan MS, Friede T, Filippatos G, Lindenfeld J, et al. Percutaneous Mitral Valve Annuloplasty in Patients with Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement. JACC. Heart Failure. 2021; 9: 453–462.
Papadopoulos K, Ikonomidis I, Chrissoheris M, Chalapas A, Kourkoveli P, Parissis J, et al. MitraClip and left ventricular reverse remodelling: a strain imaging study. ESC Heart Failure. 2020; 7: 1409–1418.
Gyoten T, Schenk S, Rochor K, Herwig V, Harnath A, Grimmig O, et al. Outcome comparison of mitral valve surgery and MitraClip therapy in patients with severely reduced left ventricular dysfunction. ESC Heart Failure. 2020; 7: 1781–1790.
Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg SL, et al. The REDUCE FMR Trial: A Randomized Sham-Controlled Study of Percutaneous Mitral Annuloplasty in Functional Mitral Regurgitation. JACC. Heart Failure. 2019; 7: 945–955.
Kortlandt F, Velu J, Schurer R, Van den Branden B, Bouma B, Kelder J, et al. Impact of mitral valve treatment choice on mortality according to aetiology. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2019; 14: 1733–1739.
Iung B, Armoiry X, Vahanian A, Boutitie F, Mewton N, Trochu JN, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. European Journal of Heart Failure. 2019; 21: 1619–1627.
Hubert A, Galli E, Leurent G, Corbineau H, Auriane B, Guillaume L, et al. Left ventricular function after correction of mitral regurgitation: Impact of the clipping approach. Echocardiography (Mount Kisco, N.Y.). 2019; 36: 2010–2018.
Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. The New England Journal of Medicine. 2018; 379: 2307–2318.
Kamperidis V, van Wijngaarden SE, van Rosendael PJ, Kong WKF, Regeer MV, van der Kley F, et al. Mitral valve repair for secondary mitral regurgitation in non-ischaemic dilated cardiomyopathy is associated with left ventricular reverse remodelling and increase of forward flow. European Heart Journal. Cardiovascular Imaging. 2018; 19: 208–215.
Asgar AW, Khairy P, Guertin MC, Cournoyer D, Ducharme A, Bonan R, et al. Clinical outcomes and economic impact of transcatheter mitral leaflet repair in heart failure patients. Journal of Medical Economics. 2017; 20: 82–90.
Ondrus T, Bartunek J, Vanderheyden M, Stockman B, Kotrc M, Van Praet F, et al. Minimally invasive mitral valve repair for functional mitral regurgitation in severe heart failure: MitraClip versus minimally invasive surgical approach. Interactive Cardiovascular and Thoracic Surgery. 2016; 23: 784–789.
Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault LP, et al. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. The New England Journal of Medicine. 2016; 374: 344–353.
Giannini C, Fiorelli F, De Carlo M, Guarracino F, Faggioni M, Giordano P, et al. Comparison of Percutaneous Mitral Valve Repair Versus Conservative Treatment in Severe Functional Mitral Regurgitation. The American Journal of Cardiology. 2016; 117: 271–277.
De Bonis M, Taramasso M, Lapenna E, Denti P, La Canna G, Buzzatti N, et al. MitraClip therapy and surgical edge-to-edge repair in patients with severe left ventricular dysfunction and secondary mitral regurgitation: mid-term results of a single-centre experience†. European Journal of Cardio-thoracic Surgery: Official Journal of the European Association for Cardio-thoracic Surgery. 2016; 49: 255–262.
Armeni P, Boscolo PR, Tarricone R, Capodanno D, Maggioni AP, Grasso C, et al. Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation. International Journal of Cardiology. 2016; 209: 153–160.
Smith PK, Puskas JD, Ascheim DD, Voisine P, Gelijns AC, Moskowitz AJ, et al. Surgical treatment of moderate ischemic mitral regurgitation. The New England Journal of Medicine. 2014; 371: 2178–2188.
Bouchard D, Jensen H, Carrier M, Demers P, Pellerin M, Perrault LP, et al. Effect of systematic downsizing rigid ring annuloplasty in patients with moderate ischemic mitral regurgitation. The Journal of Thoracic and Cardiovascular Surgery. 2014; 147: 1471–1477.
Conradi L, Treede H, Rudolph V, Graumüller P, Lubos E, Baldus S, et al. Surgical or percutaneous mitral valve repair for secondary mitral regurgitation: comparison of patient characteristics and clinical outcomes. European Journal of Cardio-thoracic Surgery: Official Journal of the European Association for Cardio-thoracic Surgery. 2013; 44: 490–496; discussion 496.
Taramasso M, Denti P, Buzzatti N, De Bonis M, La Canna G, Colombo A, et al. Mitraclip therapy and surgical mitral repair in patients with moderate to severe left ventricular failure causing functional mitral regurgitation: a single-centre experience. European Journal of Cardio-thoracic Surgery: Official Journal of the European Association for Cardio-thoracic Surgery. 2012; 42: 920–926.
Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, et al. Percutaneous repair or surgery for mitral regurgitation. The New England Journal of Medicine. 2011; 364: 1395–1406.
Fattouch K, Guccione F, Sampognaro R, Panzarella G, Corrado E, Navarra E, et al. POINT: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: a randomized trial. The Journal of Thoracic and Cardiovascular Surgery. 2009; 138: 278–285.
Kamperidis V, Marsan NA, Delgado V, Bax JJ. Left ventricular systolic function assessment in secondary mitral regurgitation: left ventricular ejection fraction vs. speckle tracking global longitudinal strain. European Heart Journal. 2016; 37: 811–816.
Ueyama H, Kuno T, Takagi H, Krishnamoorthy P, Prandi FR, Palazzuoli A, et al. Prognostic value of left ventricular global longitudinal strain in mitral regurgitation: a systematic review. Heart Failure Reviews. 2023; 28: 465–483.
